Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer

• Published in: Frontiers in oncology Vol. 11; p. 656172
• Main Authors: Zeng, Yangyang, Shi, Yingying, Xu, Lu, Zeng, Yulan, Cui, Xiao, Wang, Yuan, Yang, Ningning, Zhou, Fuxiang, Zhou, Yunfeng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.05.2021
• Subjects: functional network analysis; immune infiltration; MRPL15; non-small-cell lung cancer; Oncology; prognostic value; MRPL15; immune infiltration; prognostic value; functional network analysis; non-small-cell lung cancer
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.656172

Mitochondrial ribosomal protein L15 (MRPL15), a member of mitochondrial ribosomal proteins whose abnormal expression is related to tumorigenesis. However, the prognostic value and regulatory mechanisms of MRPL15 in non-small-cell lung cancer (NSCLC) remain unclear. GEPIA, ONCOMINE, Gene Expression Omnibus (GEO), UALCAN, Kaplan-Meier plotter, PrognoScan, LinkedOmics and GeneMANIA database were utilized to explore the expression and prognostic value of MRPL15 in NSCLC. Additionally, immune infiltration patterns were evaluated ESTIMATE algorithm and TISIDB database. Furthermore, the expression and prognostic value of MRPL15 in lung cancer were validated immunohistochemistry (IHC) assays. In NSCLC, multiple cohorts including GEPIA, ONCOMINE and 8 GEO series (GSE8569, GSE101929, GSE33532, GSE27262, GSE21933, GSE19804, GSE19188, GSE18842) described that MRPL15 was up-regulated. Moreover, MRPL15 was notably linked to gender, clinical stage, lymph node status and the TP53 mutation status. And patients with high MRPL15 expression showed poor overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) and relapse-free survival (RFS) in NSCLC. Then, functional network analysis suggested that MRPL15 participated in metabolism-related pathways, DNA replication and cell cycle signaling pathways involving several kinases, miRNAs and transcription factors. Additionally, it was found that MRPL15 expression was negatively related to immune infiltration, including immune scores, stromal scores and several tumor-infiltrating lymphocytes (TILs). Furthermore, IHC results further confirmed the high MRPL15 expression and its prognostic potential in lung cancer. These findings demonstrate that high MRPL15 expression indicates poor prognosis in NSCLC and reveal potential regulatory networks as well as the negative relationship with immune infiltration. Thus, MRPL15 may be an attractive predictor and therapeutic strategy for NSCLC.